Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Licenses Sangamo’s DNA-Binding Technology For Protein Production

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech and Medarex are the only two firms with commercial licenses for the zinc finger DNA-binding protein technology.

You may also be interested in...



Sangamo Acquisition Of Edwards’ R&D Program Will Enhance Partnering Opportunities

Sangamo will acquire Edwards’ angiogenesis program based on zinc finger protein activation of the VEGF gene.

Drug Shortages Loom If Coronavirus Persists In China, Generics Execs Say

Drug shortages will become a bigger issue in a few months if ingredient supply disruptions in China persist, Bernstein analyst Gal concluded from discussions with four generic executives. 

Mallinckrodt Finds An Exit Door For Generics In Proposed Opioid Settlement

The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.

Topics

UsernamePublicRestriction

Register

PS065978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel